US4909799A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods for preventing thrombosis; and surgical implant having reduced platelet deposition characteristics
Assignee: Individual
•
Filing: 1987-09-18
•
Granted: 1990-03-20
•
Expires: 2007-09-18
Abstract
Abstract In order to improve the surface properties of small caliber vascular grafts or other surgical implants, Forskolin (or a derivative thereof) which is a power cAMP stimulating agent, is applied to the thrombogenic surfaces of the graft/implant. Forskolin as thus used is a potent antiplatelet agent significantly lowering platelet deposition on the implant.
Inventors
- 👤 Olav Thulesius
- 👤 Jan T. Christenson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 21:42
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/35; A61L; A61L33/00; A61L33/0005; A61L33/0011; A61L33/0041
Claims Analysis
Total Claims: 37
Claim 1
Independent Claim
51 words
A method for reducing the incidence of thrombosis in a patient following a surgical implant procedure on the patient comprising the steps of: applying 7B-acetoxy-8,13-epoxy-1a-6B,9a-trihydroxylabd-14-en-11-one (Forskolin) or a derivative thereof to a surgical implant, and thereafter, implanting the surgical implant with the Forskolin or a derivative thereof thereon into the patient.
Claim 2
Independent Claim
51 words
A method for reducing the incidence of thrombosis in a patient following a surgical implant procedure on the patient comprising the steps of: applying 7B-acetoxy-8,13-epoxy-1a-6B,9a-trihydroxylabd-14-en-11-one (Forskolin) or a derivative thereof to a surgical implant, and thereafter, implanting the surgical implant with the Forskolin or a derivative thereof thereon into the patient.
Claim 3
Dependent Claim
20 words
The method of claim 1 including, said applying including soaking the surgical implant in the Forskolin or a derivative thereof.
Claim 4
Dependent Claim
23 words
The method of claim 2 including, said soaking including soaking the surgical implant in a solution of the Forskolin or a derivative thereof.
Claim 5
Dependent Claim
12 words
The method of claim 3 including, said solution being an alcohol solution.
Claim 6
Dependent Claim
10 words
The method of claim 3 including, said solution including ethanol.
Claim 7
Dependent Claim
11 words
The method of claim 5 including, said solution being 96% ethanol.
Claim 8
Dependent Claim
20 words
The method of claim 3 including, said solution having a strength of 0.05-0.15% of the Forskolin or a derivative thereof.
Claim 9
Dependent Claim
19 words
The method of claim 7 including, said solution comprising 0.1% alcoholic solution of the Forskolin or a derivative thereof.
Claim 10
Dependent Claim
12 words
The method of claim 3 including, said solution comprising an organic solvent.
Claim 11
Dependent Claim
16 words
The method of claim 9 including, said organic solvent having affinity characteristics to polyurethane or polyethylene.
Claim 12
Dependent Claim
19 words
The method of claim 3 including, said applying including after said soaking, and before said implanting, drying the implant.
Claim 13
Dependent Claim
17 words
The method of claim 11 including, said drying including allowing the implant to dry at room temperature.
Claim 14
Dependent Claim
14 words
The method of claim 1 including, said Forskolin or a derivative thereof comprising 7-0-he-misuccinyl-7-deacety-forskolin.
Claim 15
Dependent Claim
27 words
The method of claim 1 including, said Forskolin or a derivative thereof being chemically bound to polyurethane, polyethylene, or poly-L-lactic acid before being applied to the implant.
Claim 16
Dependent Claim
21 words
The method of claim 1 including, said implant comprising a by-pass graft, an artificial cardiac implant, or a therapeutic arteriovenous shunt.
Claim 17
Dependent Claim
34 words
The method of claim 1 including, said applying including coating the surface of the implant which will be in contact with blood with the Forskolin or a derivative thereof to prevent platelet aggregation thereon.
Claim 18
Dependent Claim
27 words
The method of claim 1 further comprising, applying to the implant an agent that acts synergistically with the Forskolin or the derivative thereof to prevent platelet aggregation.
Claim 19
Dependent Claim
11 words
The method of claim 17 including said agent comprising a prostaglandin.
Claim 20
Dependent Claim
14 words
The method of claim 1 including, said implant comprising a transplant from the patient.
Claim 21
Dependent Claim
15 words
The method of claim 19 including, before said coating, removing the transplant from the patient.
Claim 22
Dependent Claim
26 words
The method of claim 20 including, said transplant comprising an autologous vein graft, and said Forskolin or a derivative thereof being applied in an isotonic solution.
Claim 23
Dependent Claim
14 words
The method of claim 1 including, said Forskolin or a derivative thereof comprising Forskolin.
Claim 24
Independent Claim
45 words
A method for preventing undue platelet aggregation on a synthetic vascular graft used in cardiovascular surgery on a patient comprising the steps of: before implanting the synthetic vascular graft in the patient, applying locally to the graft 7B-acetoxy-8, 13-epoxy-1a-6, 9a-trihydroxylabd-14-en-11-one (Forskolin) or a derivative thereof.
Claim 25
Independent Claim
45 words
A method for preventing undue platelet aggregation on a synthetic vascular graft used in cardiovascular surgery on a patient comprising the steps of: before implanting the synthetic vascular graft in the patient, applying locally to the graft 7B-acetoxy-8, 13-epoxy-1a-6, 9a-trihydroxylabd-14-en-11-one (Forskolin) or a derivative thereof.
Claim 26
Dependent Claim
13 words
The method of claim 1 including, said implant comprising a synthetic vascular graft.
Claim 27
Dependent Claim
41 words
An implant device suitable for surgical implantation in a patient and showing low resulting platelet deposition thereon comprising: a surgical implant having an implant thrombogenic surface, and a coating of 7B-acetoxy-8,13-epoxy-1a-6B,9a-trihydroxylabd-14-en-11-one (Forskolin) or a derivative thereof on said implant thrombogenic surface.
Claim 28
Dependent Claim
41 words
An implant device suitable for surgical implantation in a patient and showing low resulting platelet deposition thereon comprising: a surgical implant having an implant thrombogenic surface, and a coating of 7B-acetoxy-8,13-epoxy-1a-6B,9a-trihydroxylabd-14-en-11-one (Forskolin) or a derivative thereof on said implant thrombogenic surface.
Claim 29
Dependent Claim
25 words
The implant device of claim 25 including, said coating being applied to said implant thrombogenic surface before said surgical implant is implanted in the patient.
Claim 30
Dependent Claim
16 words
The implant device of claim 25 including, said surgical implant being formed of a synthetic material.
Claim 31
Dependent Claim
12 words
The implant device of claim 27 including, said synthetic material being polytetrafluoroethylene.
Claim 32
Dependent Claim
16 words
The implant device of claim 25 including, said surgical implant comprising a transplant from the patient.
Claim 33
Dependent Claim
25 words
The implant device of claim 25 including, said surgical implant comprising a vascular graft, a cardiac implant, a cardiac assist device, or an artificial device.
Claim 34
Dependent Claim
14 words
The implant device of claim 25 including, said surgical implant comprising an auto-transplanted vessel.
Claim 35
Dependent Claim
37 words
The implant device of claim 25 including, said coating being applied b soaking said implant in a solution of the Forskolin or a derivative thereof and thereafter drying said implant before implanting said implant in the patient.
Claim 36
Dependent Claim
14 words
The implant device of claim 25 including, said surgical implant being a polytetrafloroethylene graft.
Claim 37
Dependent Claim
28 words
The implant device of claim 25 including, said surgical implant comprising a synthetic vascular graft four millimeters or less in diameter and greater than eight centimeters in length.
References Cited (Backward Citations)
US3886947A
Cited
US4088659A
Cited
US4118508A
Cited
US4134986A
Cited
US4338325A
Cited
US4221805A
Cited
US4326532A
Cited
US4536179A
Cited
US4588724A
Cited
US4751224A
Cited
US4713402A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-03-19 | 1993-09-18 | 1994-03-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-03-19 | 1997-09-18 | 1998-03-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-03-19 | 2001-09-18 | 2002-03-20 | $7700.00 | Window Closed / Lapsed |